Aviragen Therapeutics (AVIR) Reports Q4 Loss of $0.15/Share

Aviragen Therapeutics (NASDAQ: AVIR) reported Q4 EPS of ($0.15), versus ($0.18) reported last year.

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• The Gap, Inc. (GAP) Tops Q2 EPS by 3c
• Benchmark Reiterates Buy Rating on Malibu Boats (MBUU) on Significant Earnings Upside